Figure 7: Brigatinib combined with cetuximab enhanced internalization and reduced EGFR expression. | Nature Communications

Figure 7: Brigatinib combined with cetuximab enhanced internalization and reduced EGFR expression.

From: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Figure 7

(a) FACS analysis using a PE-conjugated EGFR antibody of PC9 triple-mutant cells treated with brigatinib, cetuximab, brigatinib+cetuximab for 0, 6, 24 and 48 h demonstrated a time-dependent marked decrease in surface EGFR after treatment with brigatinib+cetuximab over a period of up to 48 h, and a moderate decrease with cetuximab alone. (b) Western blotting assessment of the cells corresponding to the treatments in a. (c,d) FACS analysis and western blotting performed with MGH121-res2 cells using the same method as with the PC9 triple-mutant cells in a,b.

Back to article page